Rational design of effective therapy combining irinotecan and rapamycin to target mTOR/HIF-1 alpha axis in colon cancer

被引：0
|
作者：
Pencreach, E. [1 ]
Arrive, M. [1 ]
Raffelsberger, W. [2 ]
Lelong-Rebel, I. [3 ]
Larsen, A. K. [4 ]
Gaub, M. P. [1 ]
Guenot, D. [1 ]
Guerin, E. [1 ]
机构：
[1] INSERM, U682, Mol Biol Lab, Strasbourg, France
[2] IGBMC, Integrat Bioinformat Dept, Strasbourg, France
[3] CNRS, EA ULP 3430, Strasbourg, France
[4] INSERM, U893, Paris, France
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72527-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：185 / 185
页数：1
相关论文
共 39 条
  • [1] Rational design of effective therapy combining irinotecan and rapamycin to target mTOR/HIF-1 alpha axis in colon cancer
    Guerin, E.
    Pencreach, E.
    Raffelsberger, W.
    Kurtz, J. E.
    Nicolet, C.
    Lelong-Rebel, I.
    Gaub, M. P.
    Guenot, D.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 49 - 49
  • [2] Is irinotecan and rapamycin combination, targeting mTOR/HIF-1 alpha axis, a new effective therapy in high grade brain tumors?
    Pencreach, Erwan
    Guerin, Eric
    Guenot, Dominique
    Legrain, Michele
    Gaub, Marie Pierre
    Entz-Werle, Natacha
    CANCER RESEARCH, 2009, 69
  • [3] HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies
    Wang, Xin
    Du, Zhen-wu
    Xu, Tian-min
    Wang, Xiao-jun
    Li, Wei
    Gao, Jia-li
    Li, Jing
    Zhu, He
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Mammalian target of rapamycin (mTOR) signaling regulates HIF-1α in ovarian clear cell adenocarinoma
    Tamura, Kazuhiro
    Kano, Mika
    Yoshie, Mikihiro
    Komine, Tatsuya
    Kutsukake, Masahiko
    Tachikawa, Eiichi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 268P - 268P
  • [5] A signaling axis between RON kinase receptor and HIF-1 alpha is a potential therapeutic target in pancreatic cancer
    Kato, Akihisa
    Toyohara, Tadashi
    Sahashi, Hidenori
    Hori, Yasuki
    Yoshida, Michihiro
    Kataoka, Hiromi
    CANCER SCIENCE, 2025, 116 : 1208 - 1208
  • [6] AKT inhibition sensitizes EVI1 expressing colon cancer cells to irinotecan therapy by regulating the Akt/mTOR axis
    Voddu Pradeepa
    Shantibhusan Suresh
    Soumen Senapati
    Cellular Oncology, 2022, 45 : 659 - 675
  • [7] AKT inhibition sensitizes EVI1 expressing colon cancer cells to irinotecan therapy by regulating the Akt/mTOR axis
    Pradeepa
    Suresh, Voddu
    Senapati, Shantibhusan
    Chakraborty, Soumen
    CELLULAR ONCOLOGY, 2022, 45 (04) : 659 - 675
  • [8] HIF1 alpha mediated angiogenesis and mammalian Target of Rapamycin (mTOR) activation: implications for treatment of tuberous sclerosis
    Tee, Andrew
    Land, S. C.
    Dunlop, E. A.
    Davies, M.
    Shen, M. H.
    Sampson, J. R.
    JOURNAL OF MEDICAL GENETICS, 2007, 44 : S17 - S17
  • [9] Blocking Mammalian Target of Rapamycin (mTOR) Attenuates HIF-1α Pathways Engaged-Vascular Endothelial Growth Factor (VEGF) in Diabetic Retinopathy
    Wei, Jie
    Jiang, Hua
    Gao, Hongrui
    Wang, Guangjie
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2016, 40 (06) : 1570 - 1577
  • [10] BPA exposure enhances the metastatic aggression of ovarian cancer through the ERa/AKT/mTOR/HIF-1α signaling axis
    Xie, Xin
    Zhu, Yan
    Cheng, Huimin
    Li, Haili
    Zhang, Yadi
    Li, Wenyong
    Wu, Fengrui
    FOOD AND CHEMICAL TOXICOLOGY, 2023, 176
1234